
|Articles|August 1, 2003
Transscleral drug delivery system under development
Fort Lauderdale, FL-Efforts to develop an episcleral anecortave acetate transscleral drug delivery system (AA-TSDDD), targeted for patients with age-related macular degeneration (AMD), are progressing initially in the rhesus monkey as preliminary devices are being redesigned to decrease postoperative problems, said Timothy W. Olsen, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Study identifies 6 key genes linking air pollution to dry eye disease
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Avisi Technologies releases positive 12-month data from VITA Trial
5


















































.png)


